Workflow
BioLife Solutions(BLFS)
icon
Search documents
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
Prnewswire· 2024-12-16 13:11
BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected ...
BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary
Prnewswire· 2024-11-14 21:05
Completes the Company's strategic move away from capital equipment businessesBOTHELL, Wash., Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash."We have now completed the divestiture of all our freeze ...
BioLife Solutions(BLFS) - 2024 Q3 - Earnings Call Transcript
2024-11-13 01:41
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Rod de Greef - Chairman and Chief Executive Officer Garrie Richardson - Chief Revenue Officer Conference Call Participants Matt Stanton - Jefferies Brendan Smith - TD Cowen Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group LLC Thomas Flaten - Lake Street Capital Markets Jade Montgomery - H.C. Wainwright & Co., LLC Operator Good af ...
BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates
ZACKS· 2024-11-12 23:51
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 77.78%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.06, delivering a surprise of 57.14%.Over the last four quarters, the company has ...
BioLife Solutions(BLFS) - 2024 Q3 - Quarterly Report
2024-11-12 21:22
Table of Contents ____________________________________________________ Title of each class Trading symbol Name of exchange on which registered Common stock, par value $0.001 per share BLFS The NASDAQ Stock Market, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ____________________________________________________ FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT P ...
BioLife Solutions(BLFS) - 2024 Q3 - Quarterly Results
2024-11-12 21:12
3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports Third Quarter 2024 Financial Results Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 ...
BioLife Solutions Reports Third Quarter 2024 Financial Results
Prnewswire· 2024-11-12 21:05
Cell Processing revenue grew 6% sequentially to $19.0 million; 43% increase compared to 2023GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54%GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20%Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestitureConference call begins at 4:30 p.m. Eastern time todayBOTH ...
BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary
Prnewswire· 2024-11-12 13:05
Strategic divestiture heightens focus on proprietary, higher-margin cell processing productsAll-cash transaction fortifies balance sheetBOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for $73 million in cash. SciSafe generated approxi ...
BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024
Prnewswire· 2024-10-31 20:03
BOTHELL, Wash., Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's fina ...
Here's Why Momentum in BioLife Solutions (BLFS) Should Keep going
ZACKS· 2024-10-07 13:51
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock ali ...